Evenity recommended by NICE for severe osteoporosis after menopause with high risk of fracture
The National Institute for Health and Care Excellence (NICE) has recommended Evenity (romosozumab) for use by the National Health Service (NHS) in England and Wales for severe osteoporosis in people after menopause at high risk of fracture.
This recommendation makes the UCB (Euronext: UCB) and Amgen (Nasdaq: AMGN) drug the first treatment for severe osteoporosis to be made available to eligible patients since 2010, and could prevent multiple hospital visits due to repeat fractures for people at high risk of fracture.
"This group of patients at very high risk of fracture who previously had limited treatment options, will soon be offered this alternative anti-osteoporosis medicine as a first-line treatment"Osteoporosis affects almost four million people in the UK and leads to approximately 520,000 fragility fractures each year, one of the highest fracture rates in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze